Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The papain-like protease (PLpro) of SARS-CoV-2 has been identified as a pivotal enzyme in viral replication, indicating it a promising target for drug discovery. Utilizing a virtual screening strategy, compound 1 with the N-(3-(5-amino-1H-pyrazol-3-yl)phenyl) benzenesulfonamide scaffold was discovered as a hit targeting PLpro. Structural modification from virtually screened hit 1 led to the development of a series of substituted 3-phenyl-1H-5-pyrazolylamide derivatives. Notably, compounds 14h and 14e exhibited improved PLpro inhibitory activity (IC = 14.2 μM and 12.0 μM, respectively) and low cytotoxicity. Further biological evaluation revealed that compound 14e with a thiophene aldehyde group displayed potent binding activity (K = 1.86 μM). This 3-phenyl-1H-5-pyrazolylamide scaffold offers significant potential for further development as a novel class of PLpro inhibitors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2025.130293 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
9-fluorenone-based synthetic sulfonamide compounds as dual inhibitors of SARS-CoV-2 Main-Protease and Papain-like Protease.
Mol Divers
September 2025
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Tilorone, a 9-fluorenone scaffold-based molecule, is a known broad-spectrum antiviral with an IC of 180 nM against SARS-CoV-2, but its mechanism is not known. In the present study, we found it to have weak activity against PLpro (IC = 30.7 ± 7.
View Article and Find Full Text PDFDivergent resistance pathways amongst SARS-CoV-2 PLpro inhibitors highlight the need for scaffold diversity.
PLoS Pathog
September 2025
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Drug-escape, where a target evolves to escape inhibition from a drug, has the potential to lead to cross-resistance where drugs that are structurally related or share similar binding mechanisms all become less effective. PLpro inhibitors are currently under development and many emerging PLpro inhibitors are derived from GRL0617, a repurposed SARS-CoV PLpro inhibitor with moderate activity against SARS-CoV-2. Two leading derivatives, PF-07957472 and Jun12682, demonstrate low nanomolar activity and display activity in mice.
View Article and Find Full Text PDFPotent inhibition of SARS-CoV-2 proteases PL and 3CL by selected gold(III)-dithiocarbamato complexes showing strong and selective antiviral activity against HCoV-OC43.
J Inorg Biochem
December 2025
Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, 38106 Braunschweig, Germany. Electronic address:
Selected gold(III)-dithiocarbamato complexes were identified as potent inhibitors of two critical enzymes involved in the SARS-CoV-2 replication cycle, the papain-line protease (PL) and the 3-chymotrypsin-like protease (3CL), showing exceptional inhibition of PL with IC values in the range of 0.1-0.2 μM and rather moderate activity against 3CL (IC values 8-9 μM).
View Article and Find Full Text PDFViral determinants of cis- and trans-cleavage by SARS-CoV-2 Nsp3 and an on-off reporter for monitoring intracellular protease activity.
Antiviral Res
October 2025
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microorganisms and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, 200032, China; Shanghai Public Health Cli
Non-structural protein 3 (nsp3), the largest multifunctional membrane-associated protein encoded by coronaviruses, contains a papain-like protease (PLpro) domain that cleaves viral polypeptides at the nsp1/nsp2, nsp2/nsp3 and nsp3/nsp4 junctions, as well as host substrates such as polyubiquitin chains and ISG15. While host substrate recognition by PLpro is well characterized, the processes by which PLpro identifies and interacts with membrane-associated viral substrates remains poorly defined. In this study, we developed full-length nsp3-containg reporter constructs to investigate PLpro-mediated cleavage in a membrane context.
View Article and Find Full Text PDFIntegrating Molecular Dynamics, Molecular Docking, and Machine Learning for Predicting SARS-CoV-2 Papain-like Protease Binders.
Molecules
July 2025
National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR 72079, USA.
Coronavirus disease 2019 (COVID-19) produced devastating health and economic impacts worldwide. While progress has been made in vaccine development, effective antiviral treatments remain limited, particularly those targeting the papain-like protease (PLpro) of SARS-CoV-2. PLpro plays a key role in viral replication and immune evasion, making it an attractive yet underexplored target for drug repurposing.
View Article and Find Full Text PDF